1. Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive study (PROspective pioglitazone clinical trial in macrovascular events): a randomized controlled trial. Lancet 2005; 366: 1279–1289. Doi: 10.1016/S0140-6736(05)67528-9.
2. Kernan WN, Viscoli CM, Furie KL, et al. Pioglitazone after ischemic stroke or transient ischemic attack. New Engl Med 2016; 374: 1321–1331.DOI:10.1056/NEJMoa1506930
3. Lincoff AM, Wolski K, Nicholls SJ, et al. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 2007; 298: 1180–1188.doi:10.1001/jama.298.10.1180.
4. De Jong M, Vander Worp HB, Vander Graaf Y, et al. Pioglitazone and the secondary prevention of cardiovascular disease. A meta-analysis of randomized-controlled trials. Cardiovascular Diabetology 2017; 16: 134. Doi:10.1186/s12933-017-0617-4.
5. Erdmann E, Harding S, Lam H, et al. Ten-year observational follow-up of PROactive: a randomized cardiovascular outcomes trial evaluating pioglitazone in type 2 diabetes. Diabetes Obes Metab 2016; 18: 266–273. Doi: 10.1111/dom.12608.
6. Morgan CL, Poole CD, Evans M, et al. What next after metformin? A retrospective evaluation of the outcome of second-line, glucose-lowering therapies in people with type 2 diabetes. J Clin Endocr Metab 2012; 97: 4605–4612. Doi: 10.1210/jc.2012-3034.
7. Strongman H, Christopher S, Majak M, et al. Pioglitazone and cause-specific risk of mortality in patients with type 2 diabetes: extended analysis from a European multidatabase cohort study. BMJ Open Diabetes Res Care 2018; 6:e000481.doi:10.1136/bmjdrc-2017-000481.
8. Yang J, Vallarino C, Bron M, et al. A comparison of all cause mortality with pioglitazone and insulin in type 2 diabetes: an expanded analysis from a retrospective cohort study. Curr Med Res Opin 2014; 30: 2223–2231. Doi:10.1185/03007995.2014.941054.
9. Mazzone T, Meyer PM, Feinstein SB, et al. Effect of pioglitazone compared with glimepiride on carotid intima media thickness in type 2 diabetes: a randomized trial. JAMA 2006; 296: 2572–2581. Doi: 10.1001/jama.296.21.joc60158.
10. Defronzo RA, Inzucchi S, Abdul-Ghani M, Nissen S. Pioglitazone: The forgotten, cost-effective cardioprotective drug for type 2 diabetes. Diabetes Vascular Disease Research 2019;16(2):133-143. Doi: 10.1177/1479164118825376.
11. DeFronzo RA. Combination therapy with GLP-1 receptor agonist and SGLT2 inhibitor. Diabetes Obes Metab 2017; 19: 1353–1362. Doi:10.1111/dom.12982
12. Clarke GD, Solis-Herrera C, Molina-Wilkins M, et al. Pioglitazone improves left ventricular diastolic function in subjects with diabetes. Diabetes Care 2017; 40: 1530–1536. Doi: 10.2337/dc17-0078.
13. Young LH, Viscoli CM, Schwartz GG, et al. Heart failure after ischemic stroke or transient ischemic attack in insulin-resistant patients without diabetes mellitus treated with pioglitazone. Circulation 2018; 138: 1210–1220. Doi: 10.1161/CIRCULATIONAHA.118.034763.
14. Betteridge DJ. Thiazolidinediones and fracture risk in patients with type 2 diabetes. Diabetic Med 2011; 28:759–771. DOI:10.1111/J.1464-5491.2010.03187.x
15. Meier C, Kraenzlin ME, Bodmer M, Jick SS, Jick H, Meier CR. Use of Thiazolidinediones and Fracture Risk. Arch Intern Med. 2008;168(8):820–825. doi:10.1001/archinte.168.8.820
16. Inzucchi SE, Lupsa B. Thiazolidinediones in the treatment of type 2 diabetes melitus. UpToDate. 2022. https://www.uptodate.com/contents/thiazolidinediones-in-the-treatment-of-type-2-diabetes-mellitus
17. Food and Drug Administration. FDA Drug Safety Communication: Updated FDA review concludes that use of type 2 diabetes medicine pioglitazone may be linked to an increased risk of bladder cancer. 2016. https://www.fda.gov/Drugs/DrugSafety/ucm519616.htm
18. Filipova E, Uzunova K, Kalinov K, Vekov T. Pioglitazone and the Risk of Bladder Cancer: A Meta-Analysis. Diabetes Ther. 2017 Aug;8(4):705-726.
19. Lewis JD, et al. Pioglitazone Use and Risk of Bladder Cancer and Other Common Cancers in Persons With Diabetes. JAMA 2015;314(3):265-77.PMID 26197187.
20. Fong DS, Contreras R. Glitazone use associated with diabetic macular edema. Am J Ophthalmol. 2009 Apr;147(4):583-586.e1.
21. Yen CL, Wu CY, See LC, et al. Pioglitazone Reduces Mortality and Adverse Events in Patients With Type 2 Diabetes and With Advanced Chronic Kidney Disease: National Cohort Study. Diabetes Care. 2020;43(10):e152-e153. doi:10.2337/dc20-1584
22. Satirapoj B, Watanakijthavonkul K, Supasyndh O. Safety and efficacy of low dose pioglitazone compared with standard dose pioglitazone in type 2 diabetes with chronic kidney disease: a randomized controlled trial. PlosOne.208;13(10):30206722.https://doi.org/10.1371/journal.pone.0206722.
23. Wutipong T et al. Effect of pioglitazone on serum FGF23 levels among patients with diabetic kidney disease: a randomized controlled trial. Int Urol Nephrol.2022. doi: 10.1007/s11355-022-03420-0.
24. Yue Zhou et al. Pioglitazone for the Primary and Secondary Prevention of Cardiovascular and Renal Outcomes in Patients with or at High Risk of Type 2 Diabetes Mellitus: A Meta-Analysis. J Clin Endocrinol Metab.2020;105(5): dgz252. Doi: 10.1210/clinem/dgz252.
25. Pioglitazone (Rx). Medscape. 2022. https://reference.medscape.com/drug/actos-pioglitazone-342726
26. Nesti L, et al. Rethinking pioglitazone as a cardioprotective agent: a new perspective on an overlooked drug. Cardiovascular Diabetology 20,109 (2021). https://doi.org/10.1186/s12933-021-01294-7.
27. Hurren KM, Dunham MW. Are thiazolidinediones a preferred drug treatment for type 2 diabetes? Expert Opinion on Pharmacotherapy 2021;22(2):131-133. Doi: 10.1080/14656566.2020.1853100.